BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

Zai prices Hong Kong offering, becomes dual-listedCross-border in-licensing company Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) raised HK$5.9 billion ($776.1 million) via an offering that will land it on the Hong Kong stock exchange. The deal’s combined...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...$15 midpoint of its proposed range. The cancer company’s lead program contains a CpG-A oligonucleotide TLR9...
...billion ($1.4 billion) in an offering that gives it a dual listing. Targets TLR9 - Toll-like receptor 9 Paul...
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9...
...into the tumor to deliver full efficacy,” Szela told BioCentury. She said that with Dynavax’s TLR9...
...$0.85 (10%) to $8.96 on Monday. Targets TLR9 -- Toll-like receptor 9 Virginia Li, Associate Editor Dynavax Technologies Corp. Toll-like receptor 9 (TLR9) TriSalus...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...be valued at roughly $325 million. The cancer company’s lead program contains a CpG-A oligonucleotide TLR9...
...monotherapy and in combination with Opdivo nivolumab to treat refractory melanoma (see “New Indications for TLR9...
...sell 5 million shares at $14-$16. Targets IRAK4 - Interleukin-1 receptor-associated kinase 4 TLR9 - Toll-like receptor 9 Paul...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...$75 million in its NASDAQ listing. The cancer company’s lead program contains a CpG-A oligonucleotide TLR9...
...Checkmate raised $85 million in its series C round last month (see “New Indications for TLR9...
BioCentury | Jul 2, 2020
Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

Bolt’s $93.5 million series C round will enable the Stanford spinout to clinically test whether its myeloid-activating antibody conjugate can provide durable treatment to a broad swath of HER2-positive solid tumor patients. Led by Sofinnova...
BioCentury | Jun 23, 2020
Distillery Therapeutics

An HIV vaccine stimulating T cell and antibody responses

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Adding T cell-stimulating heterologous viral vectors (HVVs) to an adjuvanted, HIV env-based HIV vaccine could improve the prevention of HIV infection. The HVVs comprise a vesicular stomatitis virus vector,...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital. CMP-001 contains a CpG-A oligonucleotide TLR9...
...Co. (NYSE:BMY). Longitude’s Oren Isacoff and Novo’s Nilesh Kumar joined the board. Targets TLR9 - Toll-like receptor 9 Danielle...
...Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi Ventures Omega Funds Clough Capital Partners Sectoral Asset Management Inc. American Cancer Society Toll-like receptor 9 (TLR9...
Items per page:
1 - 10 of 1273